Cart summary

You have no items in your shopping cart.

Moxifloxacin hydrochloride

SKU: orb1310715

Description

Moxifloxacin hydrochloride is a fourth-generation fluoroquinolone antibiotic with enhanced activity against Gram-positive and atypical pathogens. It is widely used in research for in vitro susceptibility testing and in vivo infection model studies. Its use has been associated with transient ALT elevations and rare cases of clinically apparent liver injury.

Research Area

Infectious Disease & Virology, Molecular Biology

Images & Validation

Key Properties

CAS Number186826-86-8
MW437.89
Purity>99.99% (May vary between batches)
FormulaC21H25ClFN3O4
SMILESO(C)C1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N3C[C@]4([C@@](C3)(NCCC4)[H])[H])C5CC5.Cl
TargetAntibiotic,Topoisomerase,Antibacterial
Solubility10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (7.54 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble);DMSO:88 mg/mL (200.96 mM);H2O:15 mg/mL (34.26 mM)

Bioactivity

In Vivo
Moxifloxacin exhibits a broad spectrum of antibacterial activity both in vitro and clinically against various pathogens, including Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, H. parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. It functions by stabilizing the DNA-drug-enzyme complex, thereby inhibiting ATP-dependent topoisomerase II (DNA gyrase) and topoisomerase IV, critical enzymes for bacterial DNA replication, transcription, repair, and recombination.
In Vitro
In a mouse model simulating human disease, treatment with Moxifloxacin combined with RIF (Rifampicin)/PZA (Pyrazinamide) shortened the therapy duration by two months compared to the standard regimen of INH (Isoniazid)/RIF/PZA. Similarly, biweekly administration of Rifampicin/Moxifloxacin/PZA led to stable cure after four months, whereas daily treatment with Rifampicin/INH/PZA resulted in cure after six months.

Storage & Handling

StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

community-acquired, chronic, bronchitis, Bacterial, BAY 128039, BAY 12-8039, BAY128039, BAY-128039, BAY12-8039 HCl, antimicrobial, Antibiotic, acute, 8-methoxyquinolone, Inhibitor, exacerbations, Moxifloxacin, Moxifloxacin HCl, Moxifloxacin Hydrochloride, Moxifloxacin hydrochloride, inhibit, Topo IV, Topo II, pneumonia, sinusitis

Similar Products

Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Moxifloxacin hydrochloride (orb1310715)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

1 ml x 10 mM (in DMSO)
¥ 1,040.00
25 mg
¥ 1,040.00
50 mg
¥ 1,300.00
100 mg
¥ 1,690.00
500 mg
¥ 2,990.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry